Pepdox
Studies
Peptides
Calculator
U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial. | Pepdox
Home
/
Search
/
PMID 40402121
U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial.
JACC. Advances
2025
PMID: 40402121
View on PubMed
DOI: 10.1016/j.jacadv.2025.101773
Semaglutide
Authors
Yan, Hongmei; Karthikeyan, Hridhay; Fan, Wenjun; Yang, Qin; Wong, Nathan D
Keywords
NHANES
cardiovascular disease (CVD)
overweight and obesity
preventable events
semaglutide